Judy P. Sy

7.5k total citations · 3 hit papers
18 papers, 6.0k citations indexed

About

Judy P. Sy is a scholar working on Ophthalmology, Radiology, Nuclear Medicine and Imaging and Molecular Biology. According to data from OpenAlex, Judy P. Sy has authored 18 papers receiving a total of 6.0k indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Ophthalmology, 6 papers in Radiology, Nuclear Medicine and Imaging and 5 papers in Molecular Biology. Recurrent topics in Judy P. Sy's work include Retinal Imaging and Analysis (6 papers), Retinal Diseases and Treatments (6 papers) and Retinal and Optic Conditions (5 papers). Judy P. Sy is often cited by papers focused on Retinal Imaging and Analysis (6 papers), Retinal Diseases and Treatments (6 papers) and Retinal and Optic Conditions (5 papers). Judy P. Sy collaborates with scholars based in United States, France and Switzerland. Judy P. Sy's co-authors include Jeffrey S. Heier, Peter K. Kaiser, Mark Michels, David M. Brown, G. Soubrane, Robert Y. Kim, Susan Schneider, Tsontcho Ianchulev, Quan Dong Nguyen and Amy Chen Rundle and has published in prestigious journals such as New England Journal of Medicine, PEDIATRICS and American Journal of Epidemiology.

In The Last Decade

Judy P. Sy

18 papers receiving 5.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration

2006 2.8k citations David M. Brown, Peter K. Kaiser et al. New England Journal of Medicine profile →
Ranibizumab for Diabetic Macular Edema

2012 1.2k citations Quan Dong Nguyen, David M. Brown et al. Ophthalmology profile →
Ranibizumab versus Verteporfin Photodynamic Therapy for Neovascular Age-Related Macular Degeneration: Two-Year Results of the ANCHOR Study

2008 1.1k citations David M. Brown, Mark Michels et al. Ophthalmology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Judy P. Sy United States	13	5.2k	4.1k	958	302	221	18	6.0k
José Garcia-Arumı́ Spain	39	3.9k 0.7×	2.8k 0.7×	881 0.9×	96 0.3×	260 1.2×	171	4.6k
Michael J. Cooney United States	24	3.3k 0.6×	2.3k 0.5×	442 0.5×	145 0.5×	114 0.5×	41	4.0k
Andrew A. Moshfeghi United States	30	2.9k 0.6×	1.9k 0.5×	567 0.6×	177 0.6×	165 0.7×	111	3.5k
V. Diana United States	33	3.3k 0.6×	1.8k 0.4×	487 0.5×	181 0.6×	172 0.8×	126	3.6k
Panagiotis Theodossiadis Greece	32	2.9k 0.6×	2.0k 0.5×	445 0.5×	144 0.5×	109 0.5×	213	3.4k
Lihteh Wu Costa Rica	31	3.3k 0.6×	2.4k 0.6×	402 0.4×	82 0.3×	101 0.5×	136	3.6k
Robert Vitti United States	27	4.8k 0.9×	3.7k 0.9×	697 0.7×	85 0.3×	192 0.9×	60	5.1k
V. Diana United States	28	2.1k 0.4×	1.5k 0.4×	472 0.5×	55 0.2×	116 0.5×	69	2.5k
Roman G. Rubio United States	25	6.6k 1.2×	4.8k 1.2×	731 0.8×	32 0.1×	162 0.7×	58	7.1k
Dustan Kangave Saudi Arabia	31	1.7k 0.3×	571 0.1×	262 0.3×	82 0.3×	186 0.8×	49	2.1k

Countries citing papers authored by Judy P. Sy

Since Specialization

Citations

This map shows the geographic impact of Judy P. Sy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Judy P. Sy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Judy P. Sy more than expected).

Fields of papers citing papers by Judy P. Sy

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Judy P. Sy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Judy P. Sy. The network helps show where Judy P. Sy may publish in the future.

Co-authorship network of co-authors of Judy P. Sy

This figure shows the co-authorship network connecting the top 25 collaborators of Judy P. Sy. A scholar is included among the top collaborators of Judy P. Sy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Judy P. Sy. Judy P. Sy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

Nguyen, Quan Dong, David M. Brown, Dennis M. Marcus, et al.. (2012). Ranibizumab for Diabetic Macular Edema. Ophthalmology. 119(4). 789–801. 1222 indexed citations breakdown →

Brown, David M., Quan Dong Nguyen, Roman G. Rubio, et al.. (2011). Ranibizumab for Diabetic Macular Edema (DME): 24-Month Efficacy and Safety Results of RISE - a Phase 3 Randomized Controlled Trial. Investigative Ophthalmology & Visual Science. 52(14). 6647–6647. 1 indexed citations

Brown, Diane, Mark Michels, Peter K. Kaiser, et al.. (2009). ANCHOR STUDY GROUP. RANIBIZUMAB VERSUS VERTEPORFIN PHOTODYNAMIC THERAPY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: TWO-YEAR RESULTS OF THE ANCHOR STUDY. 116(1). 57–65. 146 indexed citations

Shah, Syed Mahmood, et al.. (2008). The RIDE and RISE Studies of the Efficacy and Safety of Intravitreal Ranibizumab (LUCENTIS®) in Clinically Significant Macular Edema With Center Involvement Secondary to Diabetes Mellitus. Investigative Ophthalmology & Visual Science. 49(13). 1562–1562. 4 indexed citations

Brown, David M., Mark Michels, Peter K. Kaiser, et al.. (2008). Ranibizumab versus Verteporfin Photodynamic Therapy for Neovascular Age-Related Macular Degeneration: Two-Year Results of the ANCHOR Study. Ophthalmology. 116(1). 57–65.e5. 1055 indexed citations breakdown →

Brown, David M., Peter K. Kaiser, Mark Michels, et al.. (2006). Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration. New England Journal of Medicine. 355(14). 1432–1444. 2769 indexed citations breakdown →

Heier, Jeffrey S., Andrew N. Antoszyk, Peter R. Pavan, et al.. (2006). Ranibizumab for Treatment of Neovascular Age-Related Macular Degeneration. Ophthalmology. 113(4). 633–642.e4. 308 indexed citations

Rogol, Alan D., Sandra L. Blethen, Judy P. Sy, & Johannes D. Veldhuis. (2003). Do growth hormone (GH) serial sampling, insulin‐like growth factor‐I (IGF‐I) or auxological measurements have an advantage over GH stimulation testing in predicting the linear growth response to GH therapy?. Clinical Endocrinology. 58(2). 229–237. 24 indexed citations

Quan, Joanne, Harm A.W.M. Tiddens, Judy P. Sy, et al.. (2001). A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities. The Journal of Pediatrics. 139(6). 813–820. 226 indexed citations

10.

Petryk, Anna, Samuel Richton, Judy P. Sy, & Sandra L. Blethen. (1999). The Effect of Growth Hormone Treatment on Stature in Aarskog Syndrome. Journal of Pediatric Endocrinology and Metabolism. 12(2). 161–5. 4 indexed citations

11.

Kemp, Stephen F. & Judy P. Sy. (1999). Analysis of Bone Age Data From National Cooperative Growth Study Substudy VII. PEDIATRICS. 104(Supplement_5). 1031–1036. 3 indexed citations

12.

Frindik, J. Paul, Stephen F. Kemp, & Judy P. Sy. (1999). Effects of Recombinant Human Growth Hormone on Height and Skeletal Maturation in Growth Hormone-Deficient Children with and without Severe Pretreatment Bone Age Delay. Hormone Research in Paediatrics. 51(1). 15–19. 23 indexed citations

13.

Kaufman, Francine & Judy P. Sy. (1999). Regular Monitoring of Bone Age Is Useful in Children Treated With Growth Hormone. PEDIATRICS. 104(Supplement_5). 1039–1042. 15 indexed citations

14.

Rosenfield, Robert L., et al.. (1998). Optimizing Estrogen Replacement Treatment in Turner Syndrome. PEDIATRICS. 102(Supplement_3). 486–488. 39 indexed citations

15.

Plotnick, Leslie, Kenneth M. Attie, Sandra L. Blethen, & Judy P. Sy. (1998). Growth Hormone Treatment of Girls With Turner Syndrome: The National Cooperative Growth Study Experience. PEDIATRICS. 102(Supplement_3). 479–481. 46 indexed citations

16.

Diamond, Frank, Allen W. Root, Dorothy I. Shulman, et al.. (1998). The Role of Serial Sampling in the Diagnosis of Growth Hormone Deficiency. PEDIATRICS. 102(Supplement_3). 521–524. 5 indexed citations

17.

Hardin, Dana S. & Judy P. Sy. (1997). Effects of growth hormone treatment in children with cystic fibrosis: The National Cooperative Growth Study experience. The Journal of Pediatrics. 131(1). S65–S69. 51 indexed citations

18.

Taylor, Jeremy M. G., Judy P. Sy, Barbara R. Visscher, & Janis V. Giorgi. (1995). CD4+ T-Cell Number at the Time of Acquired Immunodeficiency Syndrome. American Journal of Epidemiology. 141(7). 645–651. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact